Guide to
Fees for Veterinary Products
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBREVIATIONS</td>
<td>3</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>4</td>
</tr>
<tr>
<td>1  AUTHORISATION OF MEDICINES</td>
<td>4</td>
</tr>
<tr>
<td>1.1 New applications</td>
<td>4</td>
</tr>
<tr>
<td>1.2 Subsequent extension applications</td>
<td>7</td>
</tr>
<tr>
<td>1.3 Addition of a food-producing animal</td>
<td>7</td>
</tr>
<tr>
<td>1.4 Switching applications</td>
<td>7</td>
</tr>
<tr>
<td>1.5 Variations</td>
<td>7</td>
</tr>
<tr>
<td>1.6 Transfer of ownership</td>
<td>9</td>
</tr>
<tr>
<td>1.7 Renewals</td>
<td>10</td>
</tr>
<tr>
<td>1.8 Parallel imports</td>
<td>10</td>
</tr>
<tr>
<td>1.9 Homeopathic product registration</td>
<td>10</td>
</tr>
<tr>
<td>1.10 Maintenance of authorisations or registrations</td>
<td>11</td>
</tr>
<tr>
<td>1.11 Batch-specific requests</td>
<td>11</td>
</tr>
<tr>
<td>1.12 Classification</td>
<td>12</td>
</tr>
<tr>
<td>1.13 Service items</td>
<td>12</td>
</tr>
<tr>
<td>1.14 Clinical field trials</td>
<td>12</td>
</tr>
<tr>
<td>2  MANUFACTURER’S LICENCE, INSPECTION AND CERTIFICATION</td>
<td>12</td>
</tr>
<tr>
<td>2.1 Manufacturer’s licence</td>
<td>12</td>
</tr>
<tr>
<td>2.2 Transfer of manufacturers’ licences</td>
<td>13</td>
</tr>
<tr>
<td>2.3 Inspections</td>
<td>13</td>
</tr>
<tr>
<td>2.4 Export and other certificates</td>
<td>14</td>
</tr>
<tr>
<td>3  MISCELLANEOUS</td>
<td>14</td>
</tr>
<tr>
<td>3.1 Technical and administrative services</td>
<td>14</td>
</tr>
<tr>
<td>3.2 Requests for information</td>
<td>15</td>
</tr>
<tr>
<td>3.3 Appeals</td>
<td>15</td>
</tr>
<tr>
<td>APPENDIX I  LIST OF TYPE II COMPLEX VARIATIONS</td>
<td>16</td>
</tr>
</tbody>
</table>
## ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMS</td>
<td>Concerned Member State</td>
</tr>
<tr>
<td>CVMP</td>
<td>Committee for Veterinary Medicinal Products</td>
</tr>
<tr>
<td>DCP</td>
<td>Decentralised Procedure</td>
</tr>
<tr>
<td>EDQM</td>
<td>European Directorate for the Quality of Medicines &amp; HealthCare</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GDP</td>
<td>Good Distribution Practice</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>HPRA</td>
<td>Health Products Regulatory Authority</td>
</tr>
<tr>
<td>MA</td>
<td>Marketing Authorisation</td>
</tr>
<tr>
<td>MR</td>
<td>Mutual Recognition</td>
</tr>
<tr>
<td>MRA</td>
<td>Mutual Recognition Agreement</td>
</tr>
<tr>
<td>PVPA</td>
<td>Parallel Veterinary Product Authorisation</td>
</tr>
<tr>
<td>RMS</td>
<td>Reference Member State</td>
</tr>
<tr>
<td>QP</td>
<td>Qualified Person</td>
</tr>
<tr>
<td>SPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>VPA</td>
<td>Veterinary Product Authorisation</td>
</tr>
</tbody>
</table>
INTRODUCTION

The Health Products Regulatory Authority is the competent authority for the authorisation of medicinal products for veterinary use. This guide is intended to assist applicants in identifying the correct category of fee to accompany applications for authorisation. It follows the order of the fees in the ‘Fee Application Form (Veterinary)’ and uses the fee code numbers in that form.

In this document, the term 'VPA range' means that the veterinary product authorisations belong to the same VPA company and have the same product trade name and active substance(s).

1 AUTHORISATION OF MEDICINES

1.1 New applications

1.1.1 Reduced dossier – standard

Fee codes 551-553, 555-558, 561-565, 567 and 568 apply to applications for veterinary medicinal products containing established active substances which are already licensed in Ireland and which are submitted under the following articles of Directive 2001/82/EC:
- Article 13.1 (generics, including generics referring to an EU reference product).
- Article 13c (informed consent).

Codes 551-553 apply to national applications and the initial 120-day ‘assessment step 1’ of applications in the decentralised procedure where Ireland is the reference Member State (RMS).

Codes 555-557 apply to mutual recognition applications made to the HPRA where Ireland is a concerned Member State (CMS).

Within these two fee code groups, the fee categories are structured as follows. The basic fee codes apply to the initial application for the first form, strength and target species in a range. The codes for ‘each additional form at the same time’ apply to each application for an additional pharmaceutical form submitted at the same time as the initial application. The codes for ‘each additional strength at the same time’ apply to each application for an additional strength submitted at the same time as the initial application.

Where a National or outgoing MRP/Decentralised application has different target species, each additional species is charged fee code 562. This fee is charged per product range included within an application and will be capped at €7,500. No additional target species fee is charged for minor species. Minor species are defined as any species that is not cattle, sheep, pigs, chickens, salmon, cats or dogs.
Code 558 applies to mutual recognition (MR) applications where Ireland is the RMS. This supplement is for the production and release of the assessment report and the handling and administration of the procedure. It is payable in addition to the appropriate national fee. Code 558 applies to the entire VPA range in the first MR procedure. National variation fees apply to any updating of the dossier prior to the MR procedure (see section 1.5.1) but no fees are charged for any updating of the dossier at the end of the MR procedure. For repeat use procedures, the fee code 558 supplement applies.

Codes 563-565, 567 and 568 apply to applications in the decentralised procedure (DCP) where Ireland is either the RMS or a CMS.

Code 568 applies to mutual recognition and decentralised applications where Ireland is the RMS. This fee is applied per CMS per product range included in the same application. It also applies to repeat use procedures for each new CMS included. This fee is capped at €7,500.

Code 561 applies to each additional drug master file or plasma master file submitted with the application. There is no charge for the first master file for each active substance in an application. As an alternative to drug master files, companies may submit certificates of suitability from EDQM. Submission of these certificates does not attract any fee.

**Example 1**, an application for an outgoing DCP for one pharmaceutical form in two strengths attracts a fee of:

- €23,000 (Product X, 10 mg tablets) (fee code 567)
- € 760 (Product X, 20 mg tablets) (fee code 564)
- €23,760

**Example 2**, an application for an outgoing DCP with two pharmaceutical forms, each form having two strengths attracts a fee of:

- €23,000 (Product X, 10 mg tablets) (fee code 567)
- € 5,900 (Product X, 10 mg/5 ml oral solution) (fee code 563)
- € 760 (Product X, 20 mg tablets) (fee code 564)
- € 760 (Product X, 20 mg/5 ml oral solution) (fee code 564)
- €30,420

**Example 3**, an application for an outgoing DCP with one pharmaceutical form, five strengths, and a total of three target species (cats, dogs, rabbits) attracts a fee of:

- €23,000 (Product X, 40mg spot-on) (fee code 567)
- € 760 (Product X, 80mg spot-on) (fee code 564)
- € 760 (Product X, 100mg spot-on) (fee code 564)
- € 760 (Product X, 250mg spot-on) (fee code 564)
- € 760 (Product X, 400mg spot-on) (fee code 564)
- € 2,500 (second target species) (fee code 562)
- €28,540
Example 4, an application for an outgoing DCP with one pharmaceutical form, three strengths, two target species, and 10 CMS attracts a fee of:

- €23,000 (Product X, 10 mg tablets) (fee code 567)
- €760 (Product X, 20 mg tablets) (fee code 564)
- €760 (Product X, 40 mg tablets) (fee code 564)
- €2,500 (second target species) (fee code 562)
- €5,000 (10 CMS) (fee code 568 x10)
- €32,020

1.1.2 Reduced dossier – complex

Codes 531–533, 535-538, 541-545, 547 and 548 apply to applications for veterinary medicinal products containing known active substances which have already been authorised in Ireland, and which are submitted under the following articles of Directive 2001/82/EC:

- Article 12.3 (full)
- Article 13.3 (‘hybrid’)
- Article 13.4 (similar biological)
- Article 13a (well-established use/bibliographical), and Article 13b (fixed combination)

The structure of the fee codes is the same as that described in section 1.1.1.

For MR applications where Ireland is the RMS, national variation fees apply to any updating of the dossier prior to the MR procedure (see section 1.5.1) but no fees are charged for any updating of the dossier at the end of the MR procedure.

For repeat use procedures, the fee code 558 supplement applies.

Hybrid and generic applications for a single product range where the hybrid relates to a new strength will be charged one single hybrid fee with the appropriate additional strength fees.

1.1.3 Complex dossier, new active substance

Codes 511-518, 520-525 and 527, apply to applications for medicinal products containing a new active substance not previously licensed in Ireland, and submitted under Article 12.3 of Directive 2001/82/EC.

The structure of the fee codes is the same as that described in section 1.1.1.

For MR applications where Ireland is the RMS, national variation fees apply to any updating of the dossier prior to the MR procedure (see section 1.5.1) but no fees are charged for any updating of the dossier at the end of the MR procedure. For repeat use procedures, the fee code 558 supplement applies.
1.2 Subsequent extension applications

Codes 529, 530, 571-575, 577 and 614-620 refer to extension applications for additional pharmaceutical forms and strengths made subsequent to the first application. The extension fee codes do not differ between applications made under different legal bases. The structure of the fee codes is the same as those described in section 1.1.1.

1.3 Addition of a food-producing animal

Code 579 refers to National, MR and DCP applications to add a food producing animal to an existing authorisation. This fee applies to each target species added to the authorisation.

1.4 Switching applications

Code 578 applies to an application for changes to the legal supply classification of a veterinary medicinal product.

1.5 Variations

Variation fees are charged for each VPA which is varied (i.e. per VPA number), and for each change applied for. No fees are charged for Type IA (immediate notification) or Type IA (annual report) variations. Fees are charged for all other variations, including safety variations, whether requested by the HPRA or not.

Grouped and work-sharing applications which include multiple variations will be charged in accordance with the relevant fee for each variation included in the group or work-sharing application, up to a maximum of €4,957 (fee code 626) per VPA range, €3,305 (fee code 630) per VPA and €4,957 (fee code 613) for work-sharing applications. The bulk fees (fee codes 626, 630 and 613) do not apply to complex Type II group or work-sharing applications.

Reduced rates apply to bulk variations where the same change is made to three or more VPAs (within a VPA range). For changes to only one or two VPAs, each change for each VPA attracts the full-rate fee. ‘VPA range’ means that the veterinary product authorisations belong to the same VPA company and have the same product trade name and active substance.

Applications for variations to authorisations that are withdrawn by the applicant, will incur an administrative fee of up to 10% of the variation fee.

The variation procedure is not applicable to the transfer of an authorisation to another VPA holder, for which a transfer of ownership application must be made (see section 1.6).
1.5.1 National variations

Variations to national product authorisations are classified according to the Commission Regulations (EC) No. 1234/2008, as minor variations Type IA and IB and major variations Type II.

Fee code 591 and the reduced rate code 592 apply to Type IB variations, i.e. those changes which are not defined as Type IA or Type II.

When the supporting data is identical to the originator and the variations are submitted at the same time, no fees are charged for variations to informed consent applications.

Code 596 is the full-rate code for complex Type II variations, which are listed in the appendix. This code is also applicable to any update to a dossier prior to an MR procedure where Ireland is the RMS and updating involves changes to the expert reports, Parts II, III or IV. The code also applies to certain 'extensions' as defined in Annex I of Commission Regulation (EC) No. 1234/2008, and listed in the appendix to this guideline. Code 606 is the reduced-rate fee which applies to bulk variations for the same change to three or more VPAs (within a VPA range).

For applications relating to the assessment of the same active substance master file for a number of products with the same company number, and where the applications have been submitted at the same time, the reduced rate fee will apply to the third and subsequent products.

Codes 597 and 601 are the full and reduced-rate codes for standard Type II variations, i.e. those changes which are classified as Type II but are not listed as complex in the appendix to this guide.

Code 597 also applies to any update to a dossier prior to an MR procedure where Ireland is the RMS and the updating involves only changes to Part IB (e.g. to bring the SPC and/or labelling into line with current guideline requirements).

Code 626 applies when the cost of multiple variations exceeds €4,957 per VPA range. This fee covers both national and MR Type IB and Type II applications.

Code 630 applies when the cost of multiple variations (submitted at the same time) to one VPA exceeds €3,305. This fee covers both national and MR Type IB and Type II applications.

Code 613 applies when the cost of a Type IB or a Type II work-sharing application exceeds €4,957. The bulk fees (fee codes 626, 630 and 613) do not apply to group or work-sharing applications that include complex type II variations (complex Type II variations are listed in the appendix).

1.5.2 Mutual recognition variations

The fees for mutual recognition (MR) variations apply to veterinary marketing authorisations granted following a mutual recognition or decentralised procedure.
1.5.2.1 MR variations where Ireland is the CMS

The mutual recognition fee codes apply to MR variations where Ireland is a CMS.

Fee code 594 and the reduced rate code 595 apply to Type IB variations, i.e. those changes which are not defined as Type IA or Type II.

Code 599 is the full-rate code for incoming complex Type II variations, which are listed in the appendix to this guide. The code also applies to certain 'extensions' as defined in Annex I of Commission Regulation (EC) No. 1234/2008, and listed in the appendix to this guideline. Code 600 is the reduced-rate fee which applies to bulk variations of the same change to three or more VPAs.

For applications relating to the assessment of the same active substance master file for a number of products with the same company number and where the applications have been submitted at the same time, the reduced rate fee will apply to the third and subsequent products.

Codes 602 and 603 are the full and reduced-rate codes for incoming standard Type II variations, i.e. those changes which are classified as Type II but are not listed in the appendix to this guide.

1.5.2.2 MR variations where Ireland is the RMS

The mutual recognition fee codes 593, 598 and 621 apply to mutual recognition variations where Ireland is the RMS. These fees are a supplement, paid in addition to the appropriate national variation fee(s) (see section 1.5.1 above), and cover the VPA range.

1.6 Transfer of ownership

These fee codes refer to the transfer of ownership of VPAs from one VPA holder to another VPA holder with a different legal entity.

Fee code 611 refers to the transfer of ownership of a VPA to a company which is related, i.e. a 'sister', 'mother' or 'daughter' company or a common corporate body formed from a takeover or merger. This fee is applied to the first marketing authorisation within the range. Fee code 652 applies to each additional marketing authorisation within the range. Codes 653 and 612 refer to the transfer between companies which are not related. These fees are applied as above.

Where bulk transfers are notified in advance, the first 10 VPA’s are charged at the normal rate and thereafter are charged at €339 (fee code 612 or 652) per transfer.

For transfer of ownership before the VPA has been granted, see section 3.1.
1.7 Renewals

There is no fee for renewal applications, however a supplement is payable for MR/decentralised applications where Ireland is the RMS. The fee code is 632 and a single supplement covers the VPA range.

1.8 Parallel imports

Code 607 applies to the first pharmaceutical form and strength of a product to be parallel imported into Ireland. A separate fee is charged for each source country applied for, whether included in the initial application or applied for subsequently.

Code 609 applies to each additional strength per country, and code 610 applies to each additional pharmaceutical form per country, whether submitted at the same time or subsequently.

Example:

€ 3,516  (Product X, 10 mg tablets, from Greece and Portugal)
€ 1,048  (Product X, 20 mg tablets, from Greece and Portugal)
€ 1,048  (Product X, cream, from Greece and Portugal)
€ 5,612

Code 654 applies to applications for parallel imports where the originator is not on the Irish market.

Code 608 refers to the transfer of ownership of parallel import licences. This fee covers the PVPA range.

Parallel import variations are charged the VPA variation fees where appropriate. See application form for a variation to a PVPA authorisation.

1.9 Homeopathic product registration

1.9.1 New applications

Codes 641 and 642 are for applications for certificate of registration for homeopathic medicinal products under the simplified registration scheme. The codes apply to national applications and decentralised applications where Ireland is CMS.

Codes 643 and 644 apply to incoming MR applications where Ireland is a CMS.

Each pharmaceutical dosage form of a product requires a separate application form and a separate fee, irrespective of the stock or potency used. An application for a series of dilutions (potencies) derived from the same stock or stocks is treated as a single application, provided all dilutions are mentioned in the same application.
1.9.2 Variations

Code 646 is for national variation applications. For bulk variations for the same change to two or more certificates, code 647 is the reduced rate fee which applies to the third and subsequent certificate.

Codes 648 and 649 apply to incoming MR variation applications where Ireland is a CMS.

1.10 Maintenance of authorisations or registrations

Codes 631, 639 and 640 are yearly fees for each VPA, which cover all aspects of routine dossier management and maintenance, including the work associated with on-going pharmacovigilance activities.

A reduced fee (code 631) is applied to the first ten VPAs and fee code 639 is applied to the subsequent VPAs. Fee code 640 applies to VPAs which are deemed to be dormant.

Dormant authorisations are defined as VPAs where the product is not marketed (excluding temporary cessation) as notified to the HPRA by 1 January of each year. Notification can be made by submitting a Marketing Status Notification form.

Where a VPA holder has less than 10 dormant authorisations, these will be charged at the dormant rate, the balance up to 10 at the reduced rate and all other authorisations charged at the standard rate.

Where a VPA holder has more than 10 dormant authorisations, these will be charged at the dormant rate, and all other authorisations charged at the standard rate.

VPAs that are withdrawn before 1 May will not be charged a maintenance fee for that year. VPAs withdrawn on 1 May and after that date will be charged a full year’s fee.

Maintenance fees are payable annually and are invoiced to VPA holders during the course of the year.

A reduced maintenance fee (code 634) applies to parallel import authorisations (PVPA).

A reduced annual maintenance fee (code 633) applies to homeopathic products.

1.11 Batch-specific requests

The fee for batch-specific requests (code 721) is payable per VPA. Where the change is identical across a number of VPAs held by the same MAH, only one batch-specific request fee will apply.
1.12 Classification

Codes 582-584 relate to classification requests for a determination of the veterinary medicinal product status of a product. Code 582 is the code for the first product in any request and code 583 is the reduced rate for additional products submitted at the same time, whether belonging to the same range of products or not. Where an appeal on a determination is made, code 584 applies.

1.13 Service items

Code 580 applies to ‘service items’, i.e. applications for radiopharmaceuticals and veterinary medicinal products with severely limited but important uses for which no alternative authorised product exists. The designation of a product as a service item must be agreed with the HPRA in advance of the submission. A turnover cut-off is also considered and companies should be prepared to divulge their expected turnover when discussing the application for service item status with the HPRA. The designation of a medicinal product as a service item is subject to review at any time.

1.14 Clinical field trials

Clinical field trial applications are made under Animal Remedies legislation, Directive 2001/82/EU and S.I. No. 786 of 2007. These are known as “research licences” under the applicable national legislation.

Code 901 applies to a research trial for a veterinary medicine containing a novel substance.

Code 902 applies to a research trial for a veterinary medicine containing an established ingredient.

Code 903 applies to variations to a current research trial licence.

2 MANUFACTURER’S LICENCE, INSPECTION AND CERTIFICATION

2.1 Manufacturer’s licence

Code 670 applies to each application for a manufacturer’s licence. There is no fee charged for the once-off renewal of an existing licence.

Codes 671, 673, 675 and 677 are annual fees payable in respect of each licence and are related to the size of the facility based on the numbers of ‘relevant employees’, defined as those involved directly in the manufacture of medicines, i.e. in production, quality control/assurance and engineering. In cases in which a manufacturer holds manufacturers’ licences for medicinal products for both human and veterinary use, the total number of relevant employees will determine the site size and the fee per annum is 1.5 times the single authorisation fee.
A company is assigned a size category at the application stage. The company must notify the HPRA of a change in size classification. The new classification will be assigned to the company from the date of notification. The HPRA may also notify the company if our records show that there has been a change in size.

Code 679 applies to variations to licences in cases where the only change is an administrative one to the licence document. A single administrative fee will also apply to a variation to remove one or more contract manufacturers/laboratories regardless of the number of licences involved. Code 680 applies to variations involving technical assessment, e.g. requiring inspection or review of supplementary data. Where the same technical variation applies to two or more licences, the second and subsequent applications are charged at the fee code 679 rate.

Fee codes 679 and 680 also apply to variations to a GMP certificate issued to manufacturers of active substances.

When adding and removing a QP or the same key personnel, code 680 applies for both changes as they are subsequent to each other. This only applies when they are being added and removed in the same application. Any other removal will be charged the administrative fee code 679.

Applications for manufacturers’ licences and variations to authorisations that are incorrect or incomplete may incur a fee of up to 10% of the application/variation fee.

An inspection fee per day/hour per member of the inspection team is payable in relation to each inspection (see section 2.3 below).

2.2 Transfer of manufacturers’ licences

Code 681 applies to the transfer of a manufacturer’s licence to a company which is related, i.e. a ‘sister’, ‘mother’ or ‘daughter’ company or a common corporate body formed from a takeover or merger. Code 682 refers to transfers between unrelated companies.

2.3 Inspections

Codes 711 and 712 apply to:
- inspections that form part of the evaluation of an application for a new manufacturer’s licence
- inspections of licensed manufacturers
- inspections of contract laboratories named in manufacturers’ licences
- inspections of marketing authorisation holders and firms involved in pharmacovigilance activities
- inspections of manufacturers of active substances

An inspection fee per day/hour per member of the inspection team is payable in relation to each inspection of each site.
In addition to the fees for each day of the inspection, travel time (max of 5 hours per inspector for travel within Ireland) will be charged together with the cost of expenses, including travel costs and subsistence for the following inspections:

Inspections of sites in a country that is not part of the European Economic Area. Accommodation costs will also be charged with the expenses listed above for these inspections.
- Inspections of sites not subject to licence under the European Communities (Animal Remedies) Regulations, e.g. manufacturers of active substances, marketing authorisation holders, firms involved in pharmacovigilance activities.
- Inspections of contract laboratories.
- Inspections conducted in response to suspected non-compliance with the principles of GMP, e.g. follow-up inspections, for-cause inspections.
- Inspections performed as a result of an application to vary a licence/authorisation.
- Inspections to review engineering installations.

2.4 Export and other certificates

Code 691 is for export and other certificates, including Certificate of a Pharmaceutical Product, Free Sale Certificates, GMP Certificates for finished products and for active pharmaceutical ingredients, certificates of price, certificates of analysis and TSE declarations. There is no charge for certificates provided in relation to mutual recognition agreements (MRAs) on GMP inspection.

Code 692 is for urgent supply of the above certificates.

There is no fee charged for GMP certificates that are issued on satisfactory conclusion of an inspection. Fee codes 691 or 692 apply to requests for the reissue of a post-inspection GMP certificate.

Note: certificates for feed supplements must be obtained from the Department of Agriculture, Food and the Marine.

3 MISCELLANEOUS

3.1 Technical and administrative services

Codes 731 and 732 are daily and hourly charge-out rates which apply when the services of technical staff are sought, for example, assessments outside the authorisation process, IT consultancy. These fee codes may also apply to advice provided by the HPRA to professional advisors. These will be considered on a case-by-case basis.

Code 733 is a charge for non-routine administrative work, e.g. photocopying requested by companies, corrections required to the authorisation documents, etc. This code is also used for
the transfer of an application for a VPA before the VPA has been granted. Where there are two or more VPAs in the product range, twice the code 733 fee is charged for the entire VPA range.

3.2 Requests for information

Code 581 relates to requests to the HPRA for information from the veterinary medicinal products’ database. The fee is payable per request.

3.3 Appeals

Code 734 is the fee for a formal appeal to a decision of the Authority of the HPRA; it is refundable to the applicant if the appeal is successful.
APPENDIX I   LIST OF TYPE II COMPLEX VARIATIONS

The following are classified as complex variations. Note that the variation numbers below relate to the numbers used in the European Commission Guideline on variation categories (2010/C 17/01).

Quality Changes – I Active Substance

B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier

b) Introduction of a new manufacturer of the active substance that is supported by an ASMF.

c) The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions, which may have a potential to change important quality characteristics of the active substance, such as qualitative and/or quantitative impurity profile requiring qualification, or physico-chemical properties impacting on bioavailability.

d) New manufacturer of material for which an assessment is required of viral safety and/or TSE risk.

B.I.a.2 Changes in the manufacturing process of the active substance

b) Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product.

B.I.e.1 Introduction of a new design space or extension of an approved design space for the active substance, concerning:

a) One unit operation in the manufacturing process of the active substance including the resulting in-process controls and/or test procedures.

b) Test procedures for starting materials/reagents/intermediates and/or the active substance.

B.I.e.2 Introduction of a post approval change management protocol related to the active substance
Quality Changes – II Finished Product

B.II.a.3 Changes in the composition (excipients) of the finished product

b) Other excipients.
2. Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the medicinal product.
4. Any new excipient that includes the use of materials of human or animal origin for which assessment is required of viral safety data or TSE risk.
5. Change that is supported by a bioequivalence study.

B.II.a.5 Change in concentration of a single-dose, total use parenteral product, where the amount of active substance per unit dose (i.e. the strength) remains the same.

B.II.b.3 Change in the manufacturing process of the finished product

b) Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product.

B.II.c.3 Change in source of an excipient or reagent with TSE risk

b) Change or introduction of a TSE risk material or replacement of a TSE risk material from a different TSE risk material, not covered by a TSE certificate of suitability.

B.II.d.3 Variations related to the introduction of real-time release or parametric release in the manufacture of the finished product

B.II.e.1 Change in immediate packaging of the finished product

b) Type of container.
2. Sterile medicinal products and biological/ immunological medicinal products.

B.II.g.1 Introduction of a new design space or extension of an approved design space for the finished product, excluding biologicals, concerning:

a) One or more unit operations in the manufacturing process of the finished product including the resulting in-process controls and/or test procedures
b) Test procedures for excipients/intermediates and/or the finished product.

B.II.g.2 Introduction of a post approval change management protocol related to the finished product
Safety, Efficacy and Pharmacovigilance changes - I Veterinary medicinal products

C.I.4 Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance data – SPC sections 4.3, 4.9 and 5.1.
Only one complex fee will be charged for C.I.4 variations if the additional changes applied for are consequential to the main change.

C.I.6 Change(s) to therapeutic indication(s)
   a) Addition of a new therapeutic indication or modification of an approved one.
      (Note: complex fee not charged for a modification)

Safety, Efficacy and Pharmacovigilance changes - II Veterinary medicinal product – specific changes

C.II.1 Variations concerning a change to or addition of a non-food producing target species.

C.II.3 Changes to the withdrawal period for a veterinary medicinal product

C.II.4 Variations concerning the replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue

C.II.5 Variations concerning the replacement of a strain for a veterinary vaccine against equine influenza.

Other categories of variations where there are substantial changes may be complex and will be considered on a case by case basis.